Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David R Spigel

Showing results (31-40 of 220) with videos related to

Pageof 22
Sort By:
Cancer|June 11, 2008
Weekly treatment with bortezomib for patients with recurrent or refractory multiple myeloma: a phase 2 trial of the Minnie Pearl Cancer Research NetworkJohn D Hainsworth, David R Spigel, John Barton, et al.
Head & Neck|December 19, 2015
PRISM: Phase 2 trial with panitumumab monotherapy as second-line treatment in patients with recurrent or metastatic squamous cell carcinoma of the head and neckDanny Rischin, David R Spigel, Douglas Adkins, et al.
Cancer Investigation|June 24, 2011
A phase II trial of panobinostat, a histone deacetylase inhibitor, in the treatment of patients with refractory metastatic renal cell carcinomaJohn D Hainsworth, Jeffrey R Infante, David R Spigel, et al.
The Oncologist|May 2, 2023
A Phase Ib Dose-Escalation Study of LCL161 Plus Oral Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer and Select Gynecologic MalignanciesMelissa L Johnson, Manish R Patel, Raid Aljumaily, et al.
Clinical Advances in Hematology & Oncology : H&O|June 19, 2012
Phase II study of concurrent radiation therapy, temozolomide, and bevacizumab followed by bevacizumab/everolimus as first-line treatment for patients with glioblastomaJohn D Hainsworth, Kent C Shih, Gregg C Shepard, et al.
The Oncologist|April 30, 2010
Molecular profiling in unknown primary cancer: accuracy of tissue of origin predictionF Anthony Greco, David R Spigel, Denise A Yardley, et al.
JCO Precision Oncology|January 7, 2022
Tumor-Specific and Tumor-Agnostic Molecular Signatures Associated With Response to Immune Checkpoint InhibitorsDaniel Schlauch, Xiaotong Fu, Suzanne F Jones, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 4, 2012
Molecular gene expression profiling to predict the tissue of origin and direct site-specific therapy in patients with carcinoma of unknown primary site: a prospective trial of the Sarah Cannon research instituteJohn D Hainsworth, Mark S Rubin, David R Spigel, et al.
Clinical Breast Cancer|August 8, 2009
Weekly gemcitabine and trastuzumab in the treatment of patients with HER2-overexpressing metastatic breast cancerDenise A Yardley, Howard A Burris, Sarah Hanson, et al.
Clinical Lung Cancer|October 16, 2012
Treatment Rationale Study Design for the MetLung Trial: A Randomized, Double-Blind Phase III Study of Onartuzumab (MetMAb) in Combination With Erlotinib Versus Erlotinib Alone in Patients Who Have Received Standard Chemotherapy for Stage IIIB or IV Met-Positive Non-Small-Cell Lung CancerDavid R Spigel, Martin J Edelman, Tony Mok, et al.
Pageof 22

Showing results (31-40 of 220) with videos related to

Sort By:
Pageof 22
Cancer|June 11, 2008
Weekly treatment with bortezomib for patients with recurrent or refractory multiple myeloma: a phase 2 trial of the Minnie Pearl Cancer Research NetworkJohn D Hainsworth, David R Spigel, John Barton, et al.
Head & Neck|December 19, 2015
PRISM: Phase 2 trial with panitumumab monotherapy as second-line treatment in patients with recurrent or metastatic squamous cell carcinoma of the head and neckDanny Rischin, David R Spigel, Douglas Adkins, et al.
Cancer Investigation|June 24, 2011
A phase II trial of panobinostat, a histone deacetylase inhibitor, in the treatment of patients with refractory metastatic renal cell carcinomaJohn D Hainsworth, Jeffrey R Infante, David R Spigel, et al.
The Oncologist|May 2, 2023
A Phase Ib Dose-Escalation Study of LCL161 Plus Oral Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer and Select Gynecologic MalignanciesMelissa L Johnson, Manish R Patel, Raid Aljumaily, et al.
Clinical Advances in Hematology & Oncology : H&O|June 19, 2012
Phase II study of concurrent radiation therapy, temozolomide, and bevacizumab followed by bevacizumab/everolimus as first-line treatment for patients with glioblastomaJohn D Hainsworth, Kent C Shih, Gregg C Shepard, et al.
The Oncologist|April 30, 2010
Molecular profiling in unknown primary cancer: accuracy of tissue of origin predictionF Anthony Greco, David R Spigel, Denise A Yardley, et al.
JCO Precision Oncology|January 7, 2022
Tumor-Specific and Tumor-Agnostic Molecular Signatures Associated With Response to Immune Checkpoint InhibitorsDaniel Schlauch, Xiaotong Fu, Suzanne F Jones, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 4, 2012
Molecular gene expression profiling to predict the tissue of origin and direct site-specific therapy in patients with carcinoma of unknown primary site: a prospective trial of the Sarah Cannon research instituteJohn D Hainsworth, Mark S Rubin, David R Spigel, et al.
Clinical Breast Cancer|August 8, 2009
Weekly gemcitabine and trastuzumab in the treatment of patients with HER2-overexpressing metastatic breast cancerDenise A Yardley, Howard A Burris, Sarah Hanson, et al.
Clinical Lung Cancer|October 16, 2012
Treatment Rationale Study Design for the MetLung Trial: A Randomized, Double-Blind Phase III Study of Onartuzumab (MetMAb) in Combination With Erlotinib Versus Erlotinib Alone in Patients Who Have Received Standard Chemotherapy for Stage IIIB or IV Met-Positive Non-Small-Cell Lung CancerDavid R Spigel, Martin J Edelman, Tony Mok, et al.
Pageof 22